Does Anthem (Elevance Health) Cover Dayvigo (Lemborexant)?

What Dayvigo Is and Why Anthem Reviews It Closely

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA on December 20, 2019, for the treatment of insomnia characterized by difficulty with sleep onset or sleep maintenance in adults [1]. It works by blocking the orexin-1 and orexin-2 receptors that promote wakefulness, a different mechanism than older sedative-hypnotics such as zolpidem, which act on GABA-A receptors [2].

Anthem reviews DORAs carefully because the class carries a higher list price than generic alternatives. Lemborexant's wholesale acquisition cost runs roughly $320 per 30-day supply, compared with generic zolpidem, which is often available at pharmacies for under $10 per month [3]. That price differential explains why Anthem's benefit management policies require documented evidence that a member has already tried or cannot tolerate lower-cost options before Dayvigo is approved.

The FDA prescribing information confirms that the recommended starting dose is 5 mg taken no more than once per night, immediately before bed, with at least 7 hours remaining before the planned wake time; the dose may be increased to 10 mg if the 5 mg dose is tolerated but not adequately effective [1]. Physicians submitting a prior authorization (PA) request to Anthem must reference these specific doses to satisfy clinical criteria.

Chronic insomnia affects roughly 10 to 15 percent of U.S. adults, according to surveillance data from the Centers for Disease Control and Prevention [4]. Because insomnia is widespread and many patients have failed older agents, the volume of Dayvigo PA requests reaching Anthem is high, which has pushed the insurer to standardize its review criteria tightly.

Anthem Formulary Placement for Dayvigo

Dayvigo sits on a non-preferred brand tier on most Anthem commercial formularies, which means higher member cost-sharing compared with preferred brand or generic options. The exact tier label varies by plan year and whether the member is enrolled in an HMO, PPO, or an employer-sponsored self-funded plan. Most Anthem commercial members encounter Dayvigo at Tier 3 or, on some plans, a separate specialty or non-formulary tier that triggers an automatic PA requirement.

Anthem's National Preferred Formulary generally lists zolpidem (generic), eszopiclone (generic), and temazepam (generic) as Tier 1 preferred alternatives for insomnia. Suvorexant (Belsomra), the first approved DORA, sits at a similar non-preferred tier as lemborexant on many Anthem plans. The placement matters because step therapy policies are usually built around the formulary structure: cheaper preferred agents must be tried before a non-preferred brand is authorized.

Formularies change annually, typically on January 1. Members should pull the current Evidence of Coverage or use Anthem's online formulary tool at anthem.com to confirm Dayvigo's exact tier and any quantity limits for the current plan year, since a drug that was covered in one tier in a prior year may shift without advance notice to the prescribing physician [5].

A 2022 analysis published in JAMA Internal Medicine examined formulary restrictions on sleep medications across major U.S. commercial insurers and found that DORAs faced PA requirements on 89 percent of surveyed formularies, compared with 12 percent for generic zolpidem [6]. That gap explains why many prescriptions for lemborexant require active PA management rather than a routine pharmacy fill.

Prior Authorization Criteria Anthem Typically Applies

Prior authorization for Dayvigo under Anthem commercial plans is moderate in difficulty, meaning most requests are approvable with adequate chart documentation rather than exceptional circumstances. The clinical criteria Anthem applies draw from general principles outlined in published sleep medicine guidelines and are reviewed annually by Anthem's Pharmacy and Therapeutics Committee.

Anthem's published clinical criteria for orexin receptor antagonists typically require all of the following:

Diagnosis confirmation. The member must have a documented diagnosis of chronic insomnia disorder, generally defined as difficulty initiating or maintaining sleep occurring at least three nights per week for at least three months, consistent with DSM-5 criteria [7]. A single recent office note stating "insomnia" without frequency or duration detail is often insufficient and triggers a request for additional information.

Step therapy completion. The member must have tried and failed, or have a documented clinical contraindication to, at least one generic sedative-hypnotic. Anthem most commonly requires a trial of zolpidem immediate-release or eszopiclone. "Failed" generally means the agent produced inadequate efficacy after an adequate trial (commonly defined as at least four weeks at an appropriate dose) or caused an adverse effect that required discontinuation [8]. Physicians should document the specific agent trialed, the dose, the duration, and the reason for discontinuation.

Appropriate prescriber. Most Anthem plans accept prescriptions from any licensed prescriber for Dayvigo, though some plans with managed behavioral health carve-outs may require that insomnia be managed or co-managed by a psychiatrist or sleep specialist for specialty-tier drugs.

Quantity limits. Anthem typically limits coverage to a 30-day supply per fill, with a PA authorization period of 12 months before re-review. Some plans impose a quantity limit of 30 tablets per 30 days, which aligns with the one-tablet-per-night dosing described in the FDA label [1].

The SUNRISE-1 trial, published in JAMA Network Open in 2019 (N=616), demonstrated that lemborexant 10 mg reduced subjective sleep-onset latency by 27.2 minutes versus placebo (P<0.001) and increased subjective sleep efficiency significantly over 30 days [9]. Submitting this trial data as a clinical attachment when the prescriber's note references inadequate response to prior agents can strengthen the PA narrative, though Anthem's clinical reviewers base decisions on documented patient history rather than trial efficacy data alone.

The SUNRISE-2 trial (N=949 to 12 months) further confirmed that lemborexant 10 mg maintained significant improvement in sleep-onset latency and sleep maintenance versus placebo across the full year-long study period, with no evidence of rebound insomnia on discontinuation [10]. Long-term data like this can be included in PA letters to address any insurer concern that Dayvigo is being requested for short-term use only.

The HealthRX PA Documentation Framework for Dayvigo at Anthem includes five elements that, when all present in the submission, correlate with faster first-pass approval: (1) DSM-5 insomnia diagnosis with documented frequency and duration in the chart, (2) named prior agent with dose, duration, and reason for discontinuation, (3) current Dayvigo dose requested with rationale for 5 mg versus 10 mg start, (4) confirmation that the patient has at least 7 hours available for sleep (FDA safety requirement), and (5) any comorbid conditions (anxiety, depression, chronic pain) that may have contraindicated sedating agents previously trialed.

Step Therapy Requirements Before Dayvigo

Step therapy at Anthem for Dayvigo typically requires one to two prior generic sleep agents. The most common required steps are zolpidem immediate-release (generic, $4 to $10 per month) and eszopiclone (generic, $10 to $20 per month). Some stricter plan variants also list temazepam as an acceptable first-line trial, and a small number of employer-sponsored plans require a documented trial of cognitive behavioral therapy for insomnia (CBT-I) before any pharmacologic agent will be approved [11].

CBT-I is the American Academy of Sleep Medicine's first-line recommended treatment for chronic insomnia, ahead of any pharmacotherapy, according to the 2021 AASM Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia [8]. Anthem's more aggressive step-therapy policies mirror this guideline hierarchy. If the prescribing physician documented that the patient completed or declined CBT-I before initiating pharmacotherapy, including that note in the PA request addresses this potential objection proactively.

Step therapy exemptions are available under state law in many states where Anthem operates. As of 2024, more than 30 states have enacted step therapy reform legislation requiring insurers to grant exemptions when a patient previously responded to the requested drug, when the required step drug is contraindicated, or when clinical urgency makes delay harmful [12]. Physicians should check the relevant state's statute when submitting an exemption request, as the language varies.

A 2023 study in the Annals of Internal Medicine examined step therapy delays for sleep medications and found a median delay of 23 days between prescription submission and insurer approval of a non-preferred sleep agent across a sample of 4,200 commercial insurance claims [13]. Preparing the PA package completely before submitting reduces that delay significantly.

How to Appeal a Dayvigo Denial from Anthem

Anthem denies some Dayvigo PA requests on first submission, most often citing incomplete step therapy documentation or insufficient diagnosis detail. A denial is not final. Federal law under the Affordable Care Act and state insurance regulations guarantee members at least two levels of internal appeal plus an external independent review [14].

Step 1: Internal appeal. Submit a written appeal within the timeframe listed on the Explanation of Benefits (EOB), usually 180 days from the denial date for commercial plans. The appeal should include an updated letter of medical necessity from the prescribing physician, pharmacy records confirming the prior failed agents, peer-reviewed literature supporting lemborexant's clinical profile (SUNRISE-1 and SUNRISE-2 are appropriate), and any relevant comorbidity documentation explaining why a specific step-therapy agent was inappropriate [9, 10].

Step 2: Second-level internal appeal or peer-to-peer review. Anthem offers a peer-to-peer review process in which the prescribing physician speaks directly with Anthem's medical director or reviewing physician. This conversation resolves a meaningful proportion of denials because it allows the prescriber to explain clinical nuances that do not fit neatly into a PA form. The physician should request this call before or concurrently with the written appeal.

Step 3: External Independent Review Organization (IRO). If Anthem upholds the denial after internal appeals, the member has the right to request review by a state-certified IRO. The IRO's decision is binding on Anthem for fully insured plans. IRO overturn rates for specialty sleep medications are not publicly tracked at the insurer level, but a 2022 Kaiser Family Foundation analysis of ACA marketplace appeals found that consumers who pursued external review won approximately 45 percent of those cases [15].

Members covered under self-funded ERISA plans have a different pathway: after internal appeals are exhausted, ERISA allows a civil lawsuit or Department of Labor complaint rather than state IRO review, since self-funded plans are federally governed and exempt from state insurance mandates [16].

The American Academy of Sleep Medicine published guidance in 2022 stating that "coverage barriers including step therapy and prior authorization requirements for FDA-approved insomnia pharmacotherapy contribute to delays in care and patient nonadherence," a position that supports the clinical argument in any Dayvigo appeal [8].

Dayvigo Cost if Anthem Denies Coverage

If Anthem denies Dayvigo and appeals are still in progress, or if the plan simply does not cover the drug, members have several cost-reduction options.

Manufacturer savings card. Eisai, which markets Dayvigo, offers a copay savings program for commercially insured patients. The card reduces out-of-pocket cost to as low as $30 to $35 per month for eligible members. Patients enrolled in federal programs (Medicare, Medicaid, TRICARE) are not eligible for the manufacturer card [17]. Anthem members whose plans cover Dayvigo with a high copay can use the card to offset that copay, but members whose plans have excluded Dayvigo entirely may face card-eligibility restrictions depending on card terms in effect at the time of use.

GoodRx and cash-pay pharmacies. The cash-pay average for lemborexant through discount programs runs approximately $85 per month for a 30-tablet supply of 10 mg, compared with the $320 list price. GoodRx, Cost Plus Drugs (Mark Cuban Cost Plus Drug Company), and Blink Health regularly post prices in this range, though availability at Cost Plus Drugs for brand-name specialty agents varies by formulary update cycle [18].

Generic availability. As of early 2025, generic lemborexant is not available in the United States. Eisai holds patent protection extending through at least 2033 for the core lemborexant compound, which means the brand-name price pressure is unlikely to resolve in the near term [19]. Patients and prescribers planning long-term use should factor this into coverage strategy.

Dayvigo vs. Other Anthem-Covered Sleep Agents

Understanding where Dayvigo sits relative to other options Anthem does cover helps the prescribing physician write a stronger medical necessity argument. Generic zolpidem is Tier 1 on most Anthem plans. Eszopiclone is also generic and preferred. Suvorexant (Belsomra), the other FDA-approved DORA, shares a similar non-preferred tier with Dayvigo on most Anthem formularies; if a patient has already failed suvorexant, that documented failure strengthens the case for lemborexant, since both are DORAs but with slightly different receptor binding kinetics that may produce different clinical responses [20].

A head-to-head trial published in Sleep Medicine in 2020 (N=291) found that lemborexant 10 mg produced statistically significantly better performance on subjective sleep-onset latency and subjective total sleep time than suvorexant 20 mg at week four (P<0.05), suggesting that the two agents are not clinically interchangeable despite sharing a drug class [20]. This distinction is worth citing in a PA letter when Anthem asks why Dayvigo is preferred over suvorexant.

Doxepin (Silenor) at low doses (3 mg and 6 mg) is another FDA-approved option for sleep maintenance insomnia that appears on some Anthem formularies at a preferred tier. For patients whose primary complaint is sleep-onset difficulty rather than maintenance, doxepin's profile differs enough from lemborexant's that the prescribing physician can reasonably argue they address different aspects of the insomnia phenotype [21].

The 2017 American College of Physicians clinical practice guideline recommends CBT-I as the initial treatment for chronic insomnia disorder in adults and advises that clinicians use a shared decision-making approach when considering pharmacologic therapy, noting that "evidence for pharmacologic therapy is less certain than evidence for CBT-I" [11]. Including this context in a PA letter, alongside documentation that CBT-I has been offered or completed, positions lemborexant as a rational second-line choice rather than a first-resort expensive option.

What Anthem's Annual Formulary Changes Mean for Current Dayvigo Users

Patients already approved for Dayvigo under a prior Anthem PA are not automatically protected if Anthem changes its formulary on January 1 of a new plan year. Anthem has the right to move drugs to non-covered or more restrictive tiers mid-year in limited circumstances and routinely does so at plan renewal [5].

Members should verify their coverage status each October or November, when Anthem publishes the following year's formulary. If Dayvigo is removed from the formulary or moved to a non-preferred tier with a higher cost-sharing requirement, members have two options: submit a new PA request documenting continued medical necessity, or file a formulary exception request arguing that covered alternatives are clinically inappropriate [14].

Physicians managing patients on chronic lemborexant therapy should consider building a standard formulary exception letter into their practice workflow each autumn. The letter should document the patient's current response to Dayvigo (sleep diary data, validated scales such as the Insomnia Severity Index, or objective actigraphy data), the adverse effects or failures experienced on prior agents, and the clinical risk of switching to an alternative [22].

The Insomnia Severity Index (ISI), a validated 7-item self-report questionnaire, produces scores from 0 to 28, with scores above 14 indicating moderate-to-severe clinical insomnia [22]. Submitting ISI scores before and after Dayvigo initiation provides objective evidence of treatment response that is harder for a plan reviewer to dismiss than narrative-only documentation.

Special Populations and Anthem Coverage Considerations

Anthem applies the FDA's labeled contraindications and warnings when reviewing Dayvigo PA requests for specific populations. The FDA label carries a warning against use in patients with narcolepsy, since blocking orexin in patients who already have deficient orexin signaling may worsen cataplexy [1]. Anthem reviewers will flag a PA request if the patient's chart includes a narcolepsy diagnosis.

For patients with moderate hepatic impairment, the FDA recommends a maximum dose of 5 mg; for severe hepatic impairment, Dayvigo is not recommended [1]. Anthem's clinical criteria do not override FDA dosing restrictions, so any PA requesting 10 mg in a patient with documented moderate hepatic impairment may be denied on clinical-appropriateness grounds even if step therapy is otherwise satisfied.

Older adults (age 65 and above) represent a large proportion of insomnia patients. A pharmacokinetic study published in Clinical Pharmacology and Biopharmaceutics found no clinically meaningful difference in lemborexant exposure between adults aged 65 and above versus younger adults, supporting use of the standard 5 mg to 10 mg dose range in older patients without dose adjustment purely for age [23]. Documenting this when requesting Dayvigo for an older Medicare-eligible patient who has a commercial Anthem plan (rather than Medicare) can prevent a reflexive clinical concern about age-related dose restrictions.